Login to Your Account

Tigenix's allogeneic stem cell candidate yields positive phase III

By Nuala Moran
Staff Writer

Monday, August 24, 2015
LONDON – Tigenix NV is claiming the crown as first to deliver positive phase III data in an allogeneic stem cell therapy, reporting statistically significant results for Cx601 in the treatment of complex perianal fistulas caused by Crohn's disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription